Sanofi S.p.A., a prominent player in the global pharmaceutical industry, is headquartered in Italy and operates extensively across Europe, North America, and Asia. Founded in 2004 through the merger of Sanofi-Synthélabo and Aventis, the company has since achieved significant milestones, including advancements in biotechnology and vaccine development. Specialising in prescription medicines, vaccines, and consumer healthcare products, Sanofi is renowned for its innovative therapies in areas such as diabetes, oncology, and rare diseases. Its commitment to research and development sets it apart, enabling the launch of unique products that address unmet medical needs. With a strong market position, Sanofi continues to be recognised for its contributions to public health and its dedication to improving patient outcomes worldwide.
How does Sanofi S.p.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sanofi S.p.A.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sanofi S.p.A., headquartered in Italy, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sanofi and inherits its climate commitments and initiatives from its parent organisation. Sanofi has established various climate initiatives, including participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on renewable energy. However, there are no specific reduction targets or achievements reported at this time. As a part of its climate strategy, Sanofi is committed to addressing its carbon footprint and enhancing sustainability practices, although detailed metrics on emissions reductions are not provided. The absence of specific emissions data highlights the ongoing need for transparency and accountability in corporate climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Sanofi S.p.A.'s Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sanofi S.p.A. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.